FDA approves Genzyme’s AUBAGIO® (teriflunomide)
NOTE: This is a guest post by our sponsor, Genzyme, A Sanofi Company. They are fully funding and sponsoring the MS Awareness Seminar being organized by the Society for Multiple Sclerosis Patients in Pakistan, scheduled to take place on Saturday 30 May, 2015 at Koh-e-Noor Hall, PC Hotel Lahore, from 4:00 pm – 6:00 pm EVENT DETAILS FDA has approved Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis. U.S. Food and Drug Administration (FDA) has approved AUBAGIO®…
Teriflunomide (Aubagio)
Teriflunomide (Aubagio) given green light in Pakistan MS fraternity welcomes the news that Aubagio (Teriflunomide) has been made available in Pakistan. The treatment is now available under the Named Patient Program, from October 2014. Aubagio 14 mg is a once-daily, oral therapy indicated in the European Union and also approved by FDA for the treatment of adult patients with relapsing-remitting multiple sclerosis. “This is an exciting development for the MS community in Pakistan who face daily challenges from their debilitating…
Recent Comments